World Library  
Flag as Inappropriate
Email this Article

Extracorporeal membrane oxygenation

Article Id: WHEBN0000444349
Reproduction Date:

Title: Extracorporeal membrane oxygenation  
Author: World Heritage Encyclopedia
Language: English
Subject: Membrane technology, Artificial lung, Hypothermia, Cardiopulmonary bypass, Critical care nursing
Collection: Intensive Care Medicine, Medical Equipment, Membrane Technology
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Extracorporeal membrane oxygenation

Extracorporeal membrane oxygenation
Intervention
ICD-10-PCS Z92.81
ICD-9-CM 39.65
MeSH
MedlinePlus
HCPCS-L2 36822

In intensive care medicine, extracorporeal membrane oxygenation (ECMO) or extracorporeal life support (ECLS) is an extracorporeal technique of providing both cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange to sustain life. This intervention has mostly been used on children, but it is seeing more use in adults with cardiac and respiratory failure. ECMO works by removing blood from the persons body and artificially removing the carbon dioxide and oxygenating red blood cells. Generally it is only used in the later treatment of a person with heart or lung failure as it is solely a life-sustaining intervention.

Contents

  • Types 1
    • Veno-arterial (VA) 1.1
    • Veno-venous (VV) 1.2
  • Outcomes 2
  • Indications 3
  • Contraindications 4
  • Initiation 5
    • Cannulation 5.1
    • Titration 5.2
  • Maintenance 6
    • Special considerations 6.1
      • Blood flow 6.1.1
      • Diuresis 6.1.2
      • Left ventricular monitoring 6.1.3
  • Weaning and discontinuing 7
    • Veno-venous ECMO liberation trial 7.1
    • Veno-arterial ECMO liberation trial 7.2
  • Complications 8
  • Current findings 9
  • References 10

Types

Veno-arterial (VA) ECMO for cardiac or respiratory failure.[1]
Veno-venous (VV) ECMO for respiratory failure.[1]

There are several forms of ECMO, the two most common of which are the veno-arterial (VA) and veno-venous (VV). In both modalities, blood drained from the venous system is oxygenated outside of the body. In VA ECMO, this blood is returned to the arterial system and in VV ECMO the blood is returned to the venous system. In VV ECMO, no cardiac support is provided.

Veno-arterial (VA)

In veno-arterial ECMO – a venous cannula is usually placed in the right common femoral vein for extraction and an arterial cannula is usually placed into the right femoral artery for infusion.[2] The tip of the femoral venous cannula should be maintained near the junction of the inferior vena cava and right atrium, while the tip of the femoral arterial cannula is maintained in the iliac artery.[2] In adults accessing the femoral artery is preferred because the insertion is simpler.[2] Central VA ECMO may be used if cardiopulmonary bypass has already been established (with cannulae in the right atrium and ascending aorta)

Veno-venous (VV)

In veno-venous ECMO cannulae are usually placed in the right common femoral vein for drainage and right internal jugular vein for infusion.[3] Alternatively, a dual lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium.

Outcomes

A registry of patients that have received ECMO is maintained by the

  1. ^ a b
  2. ^ a b c
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^
  14. ^
  15. ^
  16. ^
  17. ^ a b
  18. ^
  19. ^
  20. ^
  21. ^

References

[21] ECMO has also seen its use on [20] Experiments on neonatal animals showed that ECMO treatment can lead to apoptosis of enterocytes, damage of the intestinal mucosal barrier and bacterial translocation. This might explain greater severity of systemic inflammatory response syndrome in neonates.[19] A recent study showed that a factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk.

Current findings

In infants aged less than 34 weeks of gestation, several physiologic systems are not well-developed, especially the cerebral vasculature and germinal matrix, resulting in high sensitivity to slight changes in pH, PaO2, and intracranial pressure.[17] Preterm infants are at unacceptably high risk for intraventricular hemorrhage (IVH) if administered ECMO at a gestational age less than 32 weeks.[18] Given the risk of IVH, it has become standard practice to perform a brain ultrasound prior to administering ECMO even in more mature neonatal patients.[17]

A common consequence in ECMO-treated adults is neurological injury, which may include subarachnoid hemorrhage, ischemic watershed infarctions, hypoxic-ischemic encephalopathy, unexplained coma, and brain death.[15] Bleeding occurs in 30 to 40 percent of those receiving ECMO and can be life-threatening. It is due to both the necessary continuous heparin infusion and platelet dysfunction. Meticulous surgical technique, maintaining platelet counts greater than 100,000/mm3, and maintaining the target ACT reduce the likelihood of bleeding.Heparin-induced thrombocytopenia (HIT) is increasingly common among people receiving ECMO. When HIT is suspected, the heparin infusion is usually replaced by a non-heparin anticoagulant.[16] There is retrograde blood flow in the descending aorta whenever the femoral artery and vein are used for VA ECMO. Stasis of the blood can occur if left ventricular output is not maintained, which may result in thrombosis. ECMO has yet to have proven survival benefit in adults with acute respiratory distress syndrome (ARDS). In VA ECMO, those whose cardiac function does not recover sufficiently to be weaned from ECMO may be bridged to a ventricular assist device (VAD) or transplant. A variety of complications can occur during cannulation, including vessel perforation with hemorrhage, arterial dissection, distal ischemia, and incorrect location (e.g., venous cannula within the artery), but these events occur highly infrequently.

Complications

VA ECMO trials require temporary clamping of both the drainage and infusion lines, while allowing the ECMO circuit to circulate through a bridge between the arterial and venous limbs. This prevents thrombosis of stagnant blood within the ECMO circuit. In addition, the arterial and venous lines should be flushed continuously with heparinized saline or intermittently with heparinized blood from the circuit. In general, VA ECMO trials are shorter in duration than VV ECMO trials because of the higher risk of thrombus formation

Veno-arterial ECMO liberation trial

VV ECMO trials are performed by eliminating all countercurrent sweep gas through the oxygenator. Extracorporeal blood flow remains constant, but gas transfer does not occur. They are then observed for several hours, during which the ventilator settings that are necessary to maintain adequate oxygenation and ventilation off ECMO are determined as indicated by arterial and venous blood gas results.

Veno-venous ECMO liberation trial

For those with respiratory failure, improvements in radiographic appearance, pulmonary compliance, and arterial oxyhemoglobin saturation indicate that the person may be ready to be taken off of ECMO support. For those with cardiac failure, enhanced aortic pulsatility correlates with improved left ventricular output and indicates that they may be ready to be taken off of ECMO support. Once the decision has been made to discontinue ECMO, the cannulae are removed.

Weaning and discontinuing

Left ventricular output is rigorously monitored during VA ECMO because left ventricular output can become worse.[13][14]

Left ventricular monitoring

Since most people are fluid-overloaded when ECMO is initiated, aggressive diuresis is warranted once the person is stable on ECMO. Ultrafiltration can be easily added to the ECMO circuit if the person has inadequate urine output.

Diuresis

Near-maximum flow rates are usually desired during VV ECMO to optimize oxygen delivery. In contrast, the flow rate used during VA ECMO must be high enough to provide adequate perfusion pressure and venous oxyhemoglobin saturation (measured on drainage blood) but low enough to provide sufficient preload to maintain left ventricular output.

Blood flow

VV ECMO is typically used for respiratory failure, while VA ECMO is used for cardiac failure. There are unique considerations for each type of ECMO, which influence management.

Special considerations

Once the initial respiratory and hemodynamic goals have been achieved, the blood flow is maintained at that rate. Frequent assessment and adjustments are facilitated by continuous venous oximetry, which directly measures the oxyhemoglobin saturation of the blood in the venous limb of the ECMO circuit.

A respiratory therapist takes a blood sample from a newborn in preparation for ECMO therapy.

Maintenance

Following cannulation they are connected to the ECMO circuit and the blood flow is increased until respiratory and hemodynamic status is stable.

Titration

ECMO required for complications of cardiac surgery can be placed directly into the appropriate chambers of the heart or great vessels.

Cannulae are usually placed percutaneously by the Seldinger technique. The largest cannulas that can be placed in the vessels are used in order to maximise flow and minimise pressures bernoulli equation

Cannulation

ECMO should be performed only by clinicians with training and experience in its initiation, maintenance, and discontinuation. Once it has been decided that ECMO will be initiated, the person is anticoagulated with intravenous heparin and then the cannulae are inserted. ECMO support is initiated once the cannulae are connected to the appropriate limbs of the ECMO circuit.

Initiation

  1. Conditions incompatible with normal life if the person recovers
  2. Preexisting conditions that affect the quality of life (CNS status, end stage malignancy, risk of systemic bleeding with anticoagulation)
  3. Age and size
  4. Futility: those who are too sick, have been on conventional therapy too long, or have a fatal diagnosis.

Most contraindications are relative, balancing the risks of the procedure (including the risk of using valuable resources that could be used for others) vs. the potential benefits. The relative contraindications are:

Contraindications

  • Hypoxemic respiratory failure with a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2) of <100 mmHg despite optimization of the ventilator settings, including the Fraction of Inspired Oxygen (FiO2), positive end-expiratory pressure (PEEP), and inspiratory to expiratory (I:E) ratio
  • Hypercapnic respiratory failure with an arterial pH <7.20
  • Refractory cardiogenic shock
  • Cardiac arrest
  • Failure to wean from cardiopulmonary bypass after cardiac surgery
  • As a bridge to either cardiac transplantation or placement of a ventricular assist device

[12] Guidelines that describe the indications and practice of ECMO are published by the

ECMO circuit
ECMO sketch

Indications

, respiratory (VV) ECMO is concentrated in designated ECMO centres to ensure top quality care. United Kingdom In the [11][10][9] The survival rates reported are better than historical survival rates.[8] have been reported in observational and uncontrolled clinical trials.[7] Survival rates from 50—70 percent[6][5] With acute respiratory failure use of ECMO has been shown to improve survival rates.[4]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.